Neuroprotective effects of tetracyclines: Molecular targets, animal models and human disease

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 3, 2009, Pages 222-231

  Orsucci, D ^a   Calsolaro, V ^a   Mancuso, M ^a   Siciliano, G ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Mitochondria; Neurodegeneration; PARP 1; ROS; Tetracyclines

Indexed keywords

BETA1 INTERFERON; DOXYCYCLINE; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; MINOCYCLINE; MITOCHONDRIAL DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PLACEBO; REACTIVE OXYGEN METABOLITE; RILUZOLE; TETRACYCLINE DERIVATIVE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; BRAIN ATROPHY; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; GUILLAIN BARRE SYNDROME; HUMAN; HUNTINGTON CHOREA; MICROGLIA; MITOCHONDRION; MULTIPLE SCLEROSIS; MUSCULAR DYSTROPHY; NERVE DEGENERATION; NEUROMUSCULAR DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRION DISEASE; PROTEIN FUNCTION; REVIEW; SPINAL CORD INJURY;

EID: 70349487545     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709788680689     Document Type: Review

References (90)

1. Yong, V.W.; Wells, J.; Giuliani, F.; Casha, S.; Power, C.; Metz, L.M. The promise of minocycline in neurology. Lancet Neurol., 2004, 3, 744-51.
2. Mancuso, M.; Coppede, F.; Migliore, L.; Siciliano, G.; Murri, L. Mitochondrial dysfunction, oxidative stress and neurodegeneration. J. Alzheimer's Dis., 2006, 10, 59-73.
3. Alano, C.C.; Kauppinen, T.M.; Valls, A.V.; Swanson, R.A. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl. Acad. Sci. USA, 2006, 103, 9685-90.
4. 2+-dependent generation of mitochondrial reactive oxygen species serves as a signal for poly(ADP-ribose) polymerase-1 activation during glutamate excitotoxicity. J. Physiol., 2007, 585, 741-58.
5. DiMauro, S.; Schon, E.A. Mitochondrial respiratory-chain diseases. N. Engl. J. Med., 2003, 348, 2656-68.
6. Lackner, L.L.; Nunnari, J.M. The molecular mechanism and cellular functions of mitochondrial division. Biochim. Biophys. Acta, 2009, in press.
7. Noji, H.; Yoshida, M. The rotary machine in the cell, ATP synthase. J. Biol. Chem., 2001, 276, 1665-8.
8. Mancuso, M.; Orsucci, D.; Siciliano, G.; Murri L. Mitochondria, mitochondrial DNA and Alzheimer's disease. What comes first? Curr. Alzheimer Res., 2008, 5, 457-68.
9. Krantic, S.; Mechawar, N.; Reix, S.; Quirion, R. Molecular basis of programmed cell death involved in neurodegeneration. Trends Neurosci., 2005, 28, 670-6.
10. Ricci, J.E.; Munoz-Pinedo, C.; Fitzgerald, P.; Bailly-Maitre, B.; Perkins, G.A.; Yadava, N.; Scheffler, I.E.; Ellisman, M.H.; Green, D.R. Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell, 2004, 117, 773-86.
11. Wang, H.; Yu, S.W.; Koh, D.W.; Lew, J.; Coombs, C.; Bowers, W.; Federoff, H.J.; Poirier, G.G.; Dawson, T.M.; Dawson, V.L. Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J. Neurosci., 2004, 24, 10963-73.
12. Mancuso, M.; Filosto, M.; Orsucci, D.; Siciliano, G. Mitochondrial DNA sequence variation and neurodegeneration. Hum. Genomics, 2008, 3, 71-8.
13. Blum, D.; Chtarto, A.; Tenenbaum, L.; Brotchi, J.; Levivier, M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol. Dis., 2004, 17, 359-66.
14. Liu, Z.; Fan, Y.; Won, S.J.; Neumann, M.; Hu, D.; Zhou, L.; Weinstein, P.R.; Liu, J. Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia. Stroke, 2007, 38, 146-52.
15. Hayakawa, K.; Mishima, K.; Nozako, M.; Hazekawa, M.; Mishima, S.; Fujioka, M.; Orito, K.; Egashira, N.; Iwasaki, K.; Fujiwara, M. Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke, 2008, 39, 951-8.
16. Zhang, Z.Y.; Zhang, Z.; Fauser, U.; Schluesener, H.J. Improved outcome of EAN, an animal model of GBS, through amelioration of peripheral and central inflammation by minocycline. J. Cell. Mol. Med., 2009, 13, 341-51.
17. Viscomi, M.T.; Latini, L.; Florenzano, F.; Bernardi, G.; Molinari, M. Minocycline attenuates microglial activation but fails to mitigate degeneration in inferior olive and pontine nuclei after focal cerebellar lesion. Cerebellum, 2008, 7, 401-5.
18. Mishra, M.K.; Basu, A. Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis. J. Neurochem., 2008, 105, 1582-95.
19. Malm, T.M.; Magga, J.; Kuh, G.F.; Vatanen, T.; Koistinaho, M.; Koistinaho, J. Minocycline reduces engraftment and activation of bone marrow-derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease. Glia, 2008, 56, 1767-79.
20. Ruggieri, M.; Pica, C.; Lia, A.; Zimatore, G.B.; Modesto, M.; Di Liddo, E.; Specchio, L.M.; Livrea, P.; Trojano, M.; Avolio, C. Combination treatment of glatiramer acetate and minocycline affects phenotype expression of blood monocyte-derived dendritic cells in multiple sclerosis patients. J. Neuroimmunol., 2008, 197, 140-6.
21. Wu, J.; Yang, S.; Xi, G.; Fu, G.; Keep, R.F.; Hua, Y. Minocycline reduces intracerebral hemorrhage-induced brain injury. Neurol. Res., 2009, 31 (2), 183-8.
22. Burggraf, D.; Trinkl, A.; Dichgans, M.; Hamann, G.F. Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia. Neurobiol. Dis., 2007, 25, 506-13.
23. Murata, Y.; Rosell, A.; Scannevin, R.H.; Rhodes, K.J.; Wang, X.; Lo, E.H. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke, 2008, 39, 3372-7.
24. Minagar, A.; Alexander, J.S.; Schwendimann, R.N.; Kelley, R.E.; Gonzalez-Toledo, E.; Jimenez, J.J.; Mauro, L.; Jy, W.; Smith, S.J. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol., 2008, 65, 199-204.
25. Hu, W.; Metselaar, J.; Ben, L.H.; Cravens, P.D.; Singh, M.P.; Frohman, E.M.; Eagar, T.N.; Racke, M.K.; Kieseier, B.C.; Stüve, O. PEG minocycline-liposomes ameliorate CNS autoimmune disease. PLoS ONE, 2009, 4, e4151.
26. Lee, H.; Park, J.W.; Kim, S.P.; Lo, E.H.; Lee, S.R. Doxycycline inhibits matrix metalloproteinase-9 and laminin degradation after transient global cerebral ischemia. Neurobiol. Dis., in press.
27. Yrjanheikki, J.; Keinanen, R.; Pellikka, M.; Hokfelt, T.; Koistinaho, J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. USA, 1998, 95, 15769-74.
28. Du, Y.; Ma, Z.; Lin, S.; Dodel, R.C.; Gao, F.; Bales, K.R.; Triarhou, L.C.; Chernet, E.; Perry, K.W.; Nelson, D.L.G.; Luecke, S.; Phebus, L.A.; Bymaster, F.P.; Paul, S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2001, 98, 14669-74.
29. Jordan, J.; Fernandez-Gomez, F.J.; Ramos, M.; Ikuta, I.; Aguirre, N.; Galindo, M.F. Minocycline and cytoprotection shedding new light on a shadowy controversy. Curr. Drug. Deliv., 2007, 4, 225-31.
30. Yrjanheikki, J.; Tikka, T.; Keinanen, R.; Goldsteins, G.; Chan, P.H.; Koistinaho, J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA, 1999, 96, 13496-500.
31. Jiang, S.X.; Lertvorachon, J.; Hou, S.; Konishi, Y.; Webster, J.; Mealing, G.; Brunette, E.; Tauskela, J.; Preston, E. Chlortetracycline and demeclocycline inhibit calpains and protect mouse neurons against glutamate toxicity and cerebral ischemia. J. Biol. Chem., 2005, 280, 33811-8.
32. Morimoto, N., Shimazawa, M.; Yamashima, T.; Nagai, H.; Hara, H. Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage. Brain Res., 2005, 1044, 8-15.
33. Haroon, M.F.; Fatima, A.; Schöler, S.; Gieseler, A.; Horn, T.F.; Kirches, E.; Wolf, G.; Kreutzmann, P. Minocycline, a possible neuroprotective agent in Leber's hereditary optic neuropathy (LHON): studies of cybrid cells bearing 11,778 mutation. Neurobiol. Dis., 2007, 28, 237-50.
34. Wang, X.; Zhu, S.; Drozda, M.; Zhang, W.; Stavrovskaya, I.G.; Cattaneo, E.; Ferrante, R.J.; Kristal, B.S.; Friedlander, R.M. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. USA, 2001, 100, 10483-7.
35. Zhu, S.; Stavrovskaya, I.G.; Drozda, M.; Kim, B.Y.; Ona, V.; Li, M.; Sarang, S.; Liu, A.S.; Hartley, D.M.; Wu, D.C.; Gullans, S.; Ferrante, R.J.; Przedborski, S.; Kristal, B.S.; Friedlander, R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature, 2002, 417, 74-8.
36. Keilhoff, G.; Schild, L.; Fansa, H. Minocycline protects Schwann cells from ischemia-like injury and promotes axonal outgrowth in bioartificial nerve grafts lacking Wallerian degeneration. Exp. Neurol., 2008, 212, 189-200.
37. Gieseler, A.; Schultze, A.T.; Kupsch, K.; Haroon, M.F.; Wolf, G.; Siemen, D.; Kreutzmann, P. Inhibitory modulation of the mitochondrial permeability transition by minocycline. Biochem. Pharmacol., 2009, 77, 888-96.
38. Kraus, R.L.; Pasieczny, R.; Lariosa-Willingham, K.; Turner, M.S.; Jiang, A.; Trauger, J.W. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J. Neurochem., 2005, 94, 819-27.
39. Lai, Y.; Chen, Y.; Watkins, S.C.; Nathaniel, P.D.; Guo, F.; Kochanek, P.M.; Jenkins, L.W.; Szabó, C.; Clark, R.S. Identification of poly-ADP-ribosylated mitochondrial proteins after traumatic brain injury. J. Neurochem., 2008, 104, 1700-11.
40. Schreiber, V.; Dantzer, F.; Amé, J.C.; de Murcia, G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol., 2006, 7, 517-28.
41. Scovassi, A.I.; Diederich, M. Modulation of poly(ADP-ribosylation) in apoptotic cells. Biochem. Pharmacol., 2004, 68, 1041-7.
42. Chen, M.; Ona, V.O.; Li, M.; Ferrante, R.J.; Fink, K.B.; Zhu, S.; Bian, J.; Guo, L.; Farrell, L.A.; Hersch, S.M.; Hobbs, W.; Vonsattel, J.; Cha, J.J.; Friedlander, R. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med., 2000, 6, 797-801.
43. NITS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology, 2006, 66, 664-71.
44. Bonelli, R.M.; Hodl, A.K.; Hofmann, P.; Kapfhammer H.P. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int. Clin. Psychopharmacol., 2004, 19, 337-41.
45. Metz, L.M.; Zhang, Y.; Yeung, M.; Patry, D.G.; Bell, R.B.; Stoian, C.A.; Yong, V.W.; Patten, S.B.; Duquette, P.; Antel, J.P.; Mitchell, J.R. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol., 2004, 5, 756.
46. Zabad, R.K.; Metz, L.M.; Todoruk, T.R.; Zhang, Y.; Mitchell, J.R.; Yeung, M.; Patry, D.G.; Bell, R.B.; Yong, V.W. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult. Scler., 2007, 13, 517-26.
47. Lampl, Y.; Boaz, M.; Gilad, R.; Lorberboym, M.; Dabby, R.; Rapoport, A.; Anca-Hershkowitz, M.; Sadeh, M. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology, 2007, 69, 1404-10.
48. Forloni, G.; Iussich, S.; Awan, T.; Colombo, L.; Angeretti, N.; Girola, L.; Bertani, I.; Poli, G.; Caramelli, M.; Grazia Bruzzone, M.; Farina, L.; Limido, L.; Rossi, G.; Giaccone, G.; Ironside, J.W.; Bugiani, O.; Salmona, M.; Tagliavini, F. Tetracyclines affect prion infectivity. Proc. Natl. Acad. Sci. USA, 2002, 99, 10849-54.
49. Miyaoka, T. Clinical potential of minocycline for schizophrenia. CNS Neurol. Disord. Drug Targets, 2008, 7, 376-81.
50. Bilousova, T.; Dansie, L.; Ngo, M.; Aye, J.; Charles, J.R.; Ethell, D.W.; Ethell, I.M. Minocycline promotes dendritic spine maturation and improves behavioral performance in the fragile X mouse model. J. Med. Genet., 2009, 46, 94-102.
51. Rosa, A.; Fonseca, B.V.; Krug, T.; Manso, H.; Gouveia, L.; Albergaria, I.; Gaspar, G.; Correia, M.; Viana-Baptista, M.; Simões, R.M.; Pinto, A.N.; Taipa, R.; Ferreira, C.; Fontes, J.R.; Silva, M.R.; Gabriel, J.P.; Matos, I.; Lopes, G.; Ferro, J.M.; Vicente, A.M.; Oliveira, S.A. Mitochondrial haplogroup H1 is protective for ischemic stroke in Portuguese patients. BMC Med. Genet., 2008, 9, 57.
52. Xu, L.; Fagan, S.C.; Waller, J.L.; Edwards, D.; Borlongan, C.V.; Zheng, J.; Hill, W.D.; Feuerstein, G.; Hess, D.C. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol., 2004, 7, 13.
53. Machado, L.S.; Kozak, A.; Ergul, A.; Hess, D.C.; Borlongan, C.V.; Fagan, S.C. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci., 2006, 7, 56.
54. Nagel, S.; Su, Y.; Horstmann, S.; Heiland, S.; Gardner, H.; Koziol, J.; Martinez-Torres, F.J.; Wagner, S. Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res., 2008, 1188, 198-206.
55. Jantzie, L.L.; Cheung, P.Y.; Todd, K.G.. Doxycicline reduces cleaved caspase-3 and microglial activation in an animal model of neonatal hypoxia-ischemia. J. Cereb. Blood Flow Metab., 2005, 25, 314-24.
56. Fan, L.; Lin, S.; Pang, Y.; Rhodes, P.G.; Cai, Z. Minocycline attenuates hypoxia-ischemia-induced neurological dysfunction and brain injury in the juvenile rat. Eur. J. Neurosci., 2006, 24, 341-50.
57. Carty, M.L.; Wixey, J.A.; Colditz, P.B.; Buller, K.M. Post-insult minocycline treatment attenuates hypoxia-ischemia-induced neuroinflammation and white matter injury in the neonatal rat: a comparison of two different dose regimens. Int. J. Dev. Neurosci., 2008, 26, 477-85.
58. Power, C.; Henry, S.; Del Bigio, M.R.; Larsen, P.H.; Corbett, D.; Imai, Y.; Yong, V.W.; Peeling, J. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann. Neurol., 2003, 53, 731-42.
59. Lee, S.M.; Yune, T.Y.; Kim, S.J.; Park, D.W.; Lee, Y.K.; Kim, Y.C.; Oh, Y.J.; Markelonis, G.J.; Oh, T.H. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J. Neurotrauma, 2003, 20, 1017-27.
60. Wells, J.; Hurlbert, J.; Fehlings, M.; Young, V.W. Neuroprotection by minocycline facilitates significant recovery after traumatic spinal cord injury. Brain, 2003, 126, 1628-37.
61. Teng, Y.D.; Choi, H.; Onario, R.C.; Zhu, S.; Desilets, F.C.; Lan, S.; Woodard, E.J.; Snyder, E.Y.; Eichler, M.E.; Friedlander, R.M. Minocycline inhibits contusion-triggered mitochondrial cytocrome c release and mitigates functional deficits after spinal cord injury. Proc. Natl. Acad. Sci. USA, 2004, 101: 3071-6.
62. Yune, T.Y.; Lee, J.Y.; Jung, G.Y.; Kin, S.J.; Jiang, M.H.; Kin, Y.C.; Oh, Y.J.; Markelonis, G.J.; Oh, T.H. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J. Neurosci., 2007, 27, 7751-61.
63. Bye, N.; Habgood, M.B.; Callaway, J.K.; Malakooti, N.; Potter, A.; Kossmann, T.; Morganti-Kossmann, M.C. Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. Exp. Neurol., 2007, 204, 220-33.
64. Crack, P.J.; Gould, J.; Bye, N.; Ross, S.; Ali, U.; Habgood, M.D.; Morganti-Kossman, C.; Saunders, N.R.; Hertzog, P.J.; Victorian Neurotrauma Research Group. The genomic profile of the cerebral cortex after closed head injury in mice: effects of minocycline. J. Neural Transm., 2009, 116, 1-12.
65. Brundula, V.; Rewcastle, N.B.; Metz, L.M.; Bernard, C.C.; Yong, V.W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain, 2002, 125, 1297-308.
66. Popovic, N.; Schubart, A.; Goetz, B.D.; Zhang, S.C.; Linington, C.; Duncan, I.D. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol., 2002, 51, 215-23.
67. Nessler, S.; Dodel, R.; Bittner, A.; Reuss, S.; Du, Y.; Hemmer, B.; Sommer, N. Effect of minocycline in experimental autoimmune encephalomyelitis. Ann. Neurol., 2002, 52, 689-90.
68. Luccarini, I.; Ballerini, C.; Biagioli, T.; Biamonte, F.; Bellucci, A.; Rosi, M.C.; Grossi, C.; Massacesi, L.; Casamenti, F. Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Exp. Neurol., 2008, 211, 214-26.
69. Maier, K.; Merkler, D.; Gerber, J.; Taheri, N.; Kuhnert, A.V.; Williams, S.K.; Neush, C.; Bahr, M.; Diem, R. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol. Dis., 2007, 25, 514-25.
70. Seabrook, T.J.; Jiang, L.; Maier, M.; Lemere, C. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia, 2006, 53, 776-82.
71. Noble, W.; Garwood, C.; Stephenson, J.; Kinsey, A.M.; Hanger, D.P.; Anderton, B.H. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J., 2009, 23, 739-50.
72. Burgos-Ramos, E.; Puebla-Jiménez, L.; Arilla-Ferreiro, E. Minocycline provides protection against beta-amyloid(25-35)-induced alterations of the somatostatin signaling pathway in the rat temporal cortex. Neuroscience, 2008, 154, 1458-66.
73. Burgos-Ramos, E.; Puebla-Jiménez, L.; Arilla-Ferreiro, E. Minocycline prevents Abeta(25-35)-induced reduction of somatostatin and neprilysin content in rat temporal cortex. Life Sci., 2009, 84, 205-10.
74. Choi, Y.; Kim, H.S.; Shin, K.Y.; Kim, E.M.; Kim, M.; Kim, H.S.; Park, C.H.; Jeong, Y.H.; Yoo, J.; Lee, J.P.; Chang, K.A.; Kim, S.; Suh, Y.H. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology, 2007, 32, 2393-404.
75. Cai, Z.Y.; Yan, Y.; Sun, S.Q.; Zhang, J.; Huang, L.G.; Yan, N.; Wu, F.; Li, J.Y. Minocycline attenuates cognitive impairment and restrains oxidative stress in the hippocampus of rats with chronic cerebral hypoperfusion. Neurosci. Bull., 2008, 24, 305-13.
76. Hirsch, E.C.; Breidert, T.; Rousselet, E.; Hunot, S.; Hartmann, A.; Michel, PP. The role of glial reaction and inflammation in Parkinson's disease. Ann. N.Y. Acad. Sci., 2003, 991, 214-28.
77. Smith, D.L.; Woodman, B.; Mahal, A.; Sathasivam, K.; Ghazi-Noori, S.; Lowden, P.A.; Bates, G.P.; Hockly, E. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann. Neurol., 2003, 54, 186-96.
78. Tikka, T.M.; Vartianen, N.E.; Goldstein, G.; Oja, S.S.; Andersen, P.M.; Marklund, S.L., Koistinaho, J. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neuron disease. Brain, 2002, 125, 722-31.
79. Pontieri, F.E.; Ricci, A.; Pellicano, C.; Benincasa, D.; Buttarelli, F.R. Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurol. Sci., 2005, 26, 285-7.
80. Gordon, P.H.; Moore, D.H.; Miller, R.G.; Florence, J.M.; Verheijde, J.L.; Doorish, C.; Hilton, J.F.; Spitalny, G.M.; MacArthur, R.B.; Mitsumoto, H.; Neville, H.E.; Boylan, K.; Mozaffar, T.; Belsh, J.M.; Ravits, J.; Bedlack, R.S.; Graves, M.C.; McCluskey, L.F.; Barohn, R.J.; Tandan, R.; Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol., 2007, 6, 1045-53.
81. Ludolph, A.C.; Bendotti, C.; Blaugrund, E.; Hengerer, B.; Löffler, J.P.; Martin, J.; Meininger, V.; Meyer, T.; Moussaoui, S.; Robberecht, W.; Scott, S.; Silani, V.; Van Den Berg, L.H.; ENMC Group for the Establishment of Guidelines for the Conduct of Preclinical and Proof of Concept Studies in ALS/MND Models. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report of the 142nd ENMC international workshop. Amyotroph. Lateral. Scler., 2007, 8, 217-23.
82. Yang, L.; Sugama, S.; Chirichigno, J.W.; Gregorio, J.; Lorenzl, S.; Shin, D.H.; Browne, S.E.; Shimizu, Y.; Joh, T.H.; Beal, M.F.; Albers, D.S. Minocycline enhances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res., 2003, 74, 278-85.
83. Diguet, E.; Fernagut, P.O.; Wei, X.; Du, Y.; Rouland, R.; Gross, C.; Bezard, E.; Tison, F. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur. J. Neurosci., 2004, 19, 3266-76.
84. Tsuj, M.; Wilson, M.A.; Lange, M.S.; Johnston, M.V. Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Exp. Neurol., 2004, 189, 58-65.
85. Raghavendra, V.; Tanga, F.; DeLeo, J.A. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther., 2003, 306, 624-30.
86. Ledeboer, A.; Sloane, E.M.; Milligan, E.D.; Frank, M.G.; Mahony, J.H.; Maier, S.F.; Watkins, L.R. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain, 2005, 115, 71-83.
87. Shefer, G.; Carmelli, E.; Rauner, G.; Yablonka-Reuveni, Z.; Benayahu, D. Exercise running and tetracycline as means to enhance skeletal muscle stem cell performance after external fixation. J. Cell. Physiol., 2008, 215, 265-75.
88. Davies, J.E.; Wang, L.; Garcia-Oroz, L.; Cook, L.J.; Vacher, C.; O'Donovan, D.G.; Rubinsztein, D.C. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat. Med., 2005, 11, 672-7.
89. Girgenrath, M.; Beermann, M.L.; Vishnudas, V.K.; Homma, S.; Miller, J.B. Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Ann. Neurol., 2009, 675, 47-56.
90. Omar, A.; Johnson, L.N. Tetracycline delays ocular motility decline in chronic progressive external ophtalmoplegia. Neurology, 2007, 68, 1159-60.